Definium Therapeutics, Inc. 4

Mark Sullivan, Chief Legal Officer of Definium Therapeutics, Inc. (DFTX), received an award of 62,500 common shares as a performance share unit tranche subject to future vesting conditions.

On August 12, 2026, Mark Sullivan, Chief Legal Officer of Definium Therapeutics, Inc., reported an acquisition of 62,500 common shares at a stated price of $0.00 per share, representing the second tranche of performance share units originally granted on March 12, 2025. These shares are still subject to vesting conditions tied to Sullivan’s continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones under the Performance Share Unit Award Agreement. Following this award, Sullivan beneficially owns 383,071 common shares in a direct ownership capacity, reflecting a routine equity compensation grant rather than an open-market purchase or sale.

Filing Facts

CIK

1813814

Ticker

DFTX

Form

4

Source Type

fda

Accession

0001193125-26-345837

Alert Tier

5